(Q30249262)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27353164%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

review article

1 reference

title

Antibiotics in the clinical pipeline at the end of 2015 (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27353164%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27353164%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

Mark Blaskovich

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27353164%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

Matthew A. Cooper

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27353164%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

author name string

Mark At Blaskovich

series ordinal

2

1 reference

13 June 2017

29 June 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27353164%20AND%20SRC:MED&resulttype=core&format=json

The Journal of Antibiotics

16 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27353164%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

volume

70

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27353164%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27353164%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

page(s)

3-24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27353164%20AND%20SRC:MED&resulttype=core&format=json

Fix the antibiotics pipeline.

16 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Antibiotics in the clinical pipeline in 2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Antibiotics in the clinical pipeline in 2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Antibiotic resistance sweeping developing world

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Update on the antibiotic resistance crisis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

The antimicrobial resistance crisis: causes, consequences, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Tackling the threat of antimicrobial resistance: from policy to sustainable action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Microbiology. Sources of antimicrobial resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Surveillance of antibiotic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Nonmedical Uses of Antibiotics: Time to Restrict Their Use?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Antimicrobial resistance in humans, livestock and the wider environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

The livestock reservoir for antimicrobial resistance: a personal view on changing patterns of risks, effects of interventions and the way forward

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

The global challenge of new classes of antibacterial agents: an industry perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Antimicrobial resistance: addressing the threat to global health. Preface

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

ESKAPEing the labyrinth of antibacterial discovery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Prospects for new antibiotics: a molecule-centered perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Confronting the challenges of discovery of novel antibacterial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Therapeutic strategies to combat antibiotic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Combating multidrug-resistant bacteria: current strategies for the discovery of novel antibacterials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Speculative strategies for new antibacterials: all roads should not lead to Rome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Thiacetazone--avoid like poison or use with care?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Delamanid: a review of its use in patients with multidrug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Delamanid for Extensively Drug-Resistant Tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

In vitro and in vivo activities of the nitroimidazole CGI 17341 against Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Substrate specificity of the deazaflavin-dependent nitroreductase from Mycobacterium tuberculosis responsible for the bioreductive activation of bicyclic nitroimidazoles

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Glycopeptide antibiotics: back to the future.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Anti-cooperative ligand binding and dimerisation in the glycopeptide antibiotic dalbavancin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Oritavancin: a novel lipoglycopeptide active against Gram-positive pathogens including multiresistant strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Oritavancin exhibits dual mode of action to inhibit cell-wall biosynthesis in Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Vancomycin and oritavancin have different modes of action in Enterococcus faecium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Oritavancin: mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Locations of the hydrophobic side chains of lipoglycopeptides bound to the peptidoglycan of Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Absorption, distribution, metabolism, and excretion of the novel antibacterial prodrug tedizolid phosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Tedizolid: The First Once-Daily Oxazolidinone Class Antibiotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Discovery of torezolid as a novel 5-hydroxymethyl-oxazolidinone antibacterial agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Novel ribosomal mutations in Staphylococcus aureus strains identified through selection with the oxazolidinones linezolid and torezolid (TR-700).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Ceftolozane/Tazobactam: A New Cephalosporin and β-Lactamase Inhibitor Combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Synthesis and SAR of novel parenteral anti-pseudomonal cephalosporins: discovery of FR264205.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

In Vitro Activity of Ceftolozane Alone and in Combination with Tazobactam against Extended-Spectrum-β-Lactamase-Harboring Enterobacteriaceae.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Nemonoxacin: first global approval

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

The potential role of nemonoxacin for treatment of common infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

In vitro activity of nemonoxacin, a novel nonfluorinated quinolone antibiotic, against Chlamydia trachomatis and Chlamydia pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Finafloxacin: first global approval

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Effect of pH on the in vitro activity of and propensity for emergence of resistance to fluoroquinolones, macrolides, and a ketolide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Antibacterial activity of finafloxacin under different pH conditions against isogenic strains of Escherichia coli expressing combinations of defined mechanisms of fluoroquinolone resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

In vitro spectrum of activity of finafloxacin, a novel, pH-activated fluoroquinolone, under standard and acidic conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

High Efficacy of Finafloxacin on Helicobacter pylori Isolates at pH 5.0 Compared with That of Other Fluoroquinolones

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

In vitro activity of AVE1330A, an innovative broad-spectrum non-beta-lactam beta-lactamase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

In vitro activity of Ozenoxacin against quinolone-susceptible and quinolone-resistant gram-positive bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Solithromycin inhibition of protein synthesis and ribosome biogenesis in Staphylococcus aureus, Streptococcus pneumoniae, and Haemophilus influenzae

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

The in vitro evaluation of solithromycin (CEM-101) against pathogens isolated in the United States and Europe (2009).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Antimicrobial characterisation of solithromycin (CEM-101), a novel fluoroketolide: activity against staphylococci and enterococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

In vitro activity of the new fluoroketolide solithromycin (CEM-101) against a large collection of clinical Neisseria gonorrhoeae isolates and international reference strains, including those with high-level antimicrobial resistance: potential treatm

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

In vitro activity of solithromycin against erythromycin-resistant Streptococcus agalactiae.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

In vitro activity of the new fluoroketolide solithromycin (CEM-101) against macrolide-resistant and -susceptible Mycoplasma genitalium strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

A novel macrolide solithromycin exerts superior anti-inflammatory effect via NF-κB inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Structure-activity relationship of the aminomethylcyclines and the discovery of omadacycline

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Mechanism of action of the novel aminomethylcycline antibiotic omadacycline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Fluorocyclines. 1. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Eravacycline (TP-434) is active in vitro against biofilms formed by uropathogenic Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Structure-Activity Relationship Studies of a Series of Semisynthetic Lipopeptides Leading to the Discovery of Surotomycin, a Novel Cyclic Lipopeptide Being Developed for the Treatment of Clostridium difficile-Associated Diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Discovery and development of surotomycin for the treatment of Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Activity of a novel cyclic lipopeptide, CB-183,315, against resistant Clostridium difficile and other Gram-positive aerobic and anaerobic intestinal pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

In vitro activities of CB-183,315, vancomycin, and metronidazole against 556 strains of Clostridium difficile, 445 other intestinal anaerobes, and 56 Enterobacteriaceae species

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Effects of surotomycin on Clostridium difficile viability and toxin production in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Mode of action and bactericidal properties of surotomycin against growing and nongrowing Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Impact of Surotomycin on the Gut Microbiota of Healthy Volunteers in a Phase 1 Clinical Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Plazomicin: an investigational therapy for the treatment of urinary tract infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Synthesis and spectrum of the neoglycoside ACHN-490

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Activity of plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Carbapenem-resistant Klebsiella pneumoniae strains exhibit diversity in aminoglycoside-modifying enzymes, which exert differing effects on plazomicin and other agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

In vitro activity of plazomicin against 5,015 gram-negative and gram-positive clinical isolates obtained from patients in canadian hospitals as part of the CANWARD study, 2011-2012.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

In vitro bactericidal activity of aminoglycosides, including the next-generation drug plazomicin, against Brucella spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

TD-1792 versus vancomycin for treatment of complicated skin and skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Antistaphylococcal activity of TD-1792, a multivalent glycopeptide-cephalosporin antibiotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Combinatorial lead optimization of [1,2]-diamines based on ethambutol as potential antituberculosis preclinical candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Novel insights into the mechanism of inhibition of MmpL3, a target of multiple pharmacophores in Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Oxa, Thia, Heterocycle, and Carborane Analogues of SQ109: Bacterial and Protozoal Cell Growth Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

SQ109, a new drug lead for Chagas disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Investigations of the mode of action and resistance development of cadazolid, a new antibiotic for treatment of Clostridium difficile infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

In vitro activity of cadazolid against Clostridium difficile strains isolated from primary and recurrent infections in Stockholm, Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of Clostridium difficile infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

The mechanism of action of PA-824: Novel insights from transcriptional profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Mutations in genes for the F420 biosynthetic pathway and a nitroreductase enzyme are the primary resistance determinants in spontaneous in vitro-selected PA-824-resistant mutants of Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Delafloxacin, a non-zwitterionic fluoroquinolone in Phase III of clinical development: evaluation of its pharmacology, pharmacokinetics, pharmacodynamics and clinical efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Quinolones: action and resistance updated

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Photodynamic effects of novel XF porphyrin derivatives on prokaryotic and eukaryotic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

XF-73, a novel antistaphylococcal membrane-active agent with rapid bactericidal activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

In vitro activity of XF-73, a novel antibacterial agent, against antibiotic-sensitive and -resistant Gram-positive and Gram-negative bacterial species

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

XF-70 and XF-73, novel antibacterial agents active against slow-growing and non-dividing cultures of Staphylococcus aureus including biofilms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Investigation of the potential for mutational resistance to XF-73, retapamulin, mupirocin, fusidic acid, daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus isolates during a 55-passage study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Fungicidal photodynamic effect of a twofold positively charged porphyrin against Candida albicans planktonic cells and biofilms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Stieglitz rearrangement of N,N-dichloro-beta,beta-disubstituted taurines under mild aqueous conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Quaternary ammonium N,N-dichloroamines as topical, antimicrobial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

N-chloramines, a promising class of well-tolerated topical anti-infectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

NVC-422 inactivates Staphylococcus aureus toxins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Are pleuromutilin antibiotics finally fit for human use?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Phase II clinical study of BC-3781, a pleuromutilin antibiotic, in treatment of patients with acute bacterial skin and skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Antimicrobial activity of the investigational pleuromutilin compound BC-3781 tested against Gram-positive organisms commonly associated with acute bacterial skin and skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

In Vitro Antimicrobial Activity of a Siderophore Cephalosporin, S-649266, against Enterobacteriaceae Clinical Isolates, Including Carbapenem-Resistant Strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Peptidomimetic antibiotics target outer-membrane biogenesis in Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Protegrins: leukocyte antimicrobial peptides that combine features of corticostatic defensins and tachyplesins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

De novo design and in vivo activity of conformationally restrained antimicrobial arylamide foldamers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

De novo design of antimicrobial polymers, foldamers, and small molecules: from discovery to practical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

A synthetic antimicrobial peptidomimetic (LTX 109): stereochemical impact on membrane disruption

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

LTX-109 is a novel agent for nasal decolonization of methicillin-resistant and -sensitive Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Antimicrobial activities of twenty lysine-peptoid hybrids against clinically relevant bacteria and fungi.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

In vitro activities of LTX-109, a synthetic antimicrobial peptide, against methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, daptomycin-nonsusceptible, and linezolid-nonsusceptible Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Design at the atomic level: generation of novel hybrid biaryloxazolidinones as promising new antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Design at the atomic level: design of biaryloxazolidinones as potent orally active antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

R chi-01, a new family of oxazolidinones that overcome ribosome-based linezolid resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

New potent antibacterial oxazolidinone (MRX-I) with an improved class safety profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

In vivo antibacterial activity of MRX-I, a new oxazolidinone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Pharmacodynamic Profile of GSK2140944 against Methicillin-Resistant Staphylococcus aureus in a Murine Lung Infection Model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Determination of disk diffusion and MIC quality control guidelines for GSK2140944, a novel bacterial type II topoisomerase inhibitor antimicrobial agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Inhibition of Neisseria gonorrhoeae Type II Topoisomerases by the Novel Spiropyrimidinetrione AZD0914.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

High in vitro activity of the novel spiropyrimidinetrione AZD0914, a DNA gyrase inhibitor, against multidrug-resistant Neisseria gonorrhoeae isolates suggests a new effective option for oral treatment of gonorrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Perturbation of Staphylococcus aureus gene expression by the enoyl-acyl carrier protein reductase inhibitor AFN-1252.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Mode of Action, In Vitro Activity, and In Vivo Efficacy of AFN-1252, a Selective Antistaphylococcal FabI Inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Discovery of a novel and potent class of FabI-directed antibacterial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Drugs for bad bugs: confronting the challenges of antibacterial discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

In vitro activity of API-1252, a novel FabI inhibitor, against clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Activity of Debio1452, a FabI inhibitor with potent activity against Staphylococcus aureus and coagulase-negative Staphylococcus spp., including multidrug-resistant strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Activity of AFN-1252, a novel FabI inhibitor, against Staphylococcus aureus in an in vitro pharmacodynamic model simulating human pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

AFN-1252 is a potent inhibitor of enoyl-ACP reductase from Burkholderia pseudomallei--Crystal structure, mode of action, and biological activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

In vitro activity (MICs and rate of kill) of AFN-1252, a novel FabI inhibitor, in the presence of serum and in combination with other antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Safety, tolerability and pharmacokinetics of AFN-1252 administered as immediate release tablets in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Pharmacokinetics, pharmacodynamics and efficacy of novel FabI inhibitor AFN-1252 against MSSA and MRSA in the murine thigh infection model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Nadifloxacin: a quinolone for topical treatment of skin infections and potential for systemic use of its active isomer, WCK 771.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

In vitro activity of the quinolone WCK 771 against recent U.S. hospital and community-acquired Staphylococcus aureus pathogens with various resistance types

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Activity of the siderophore monobactam BAL30072 against multiresistant non-fermenters

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Involvement of Fe uptake systems and AmpC β-lactamase in susceptibility to the siderophore monosulfactam BAL30072 in Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Combined effects of the siderophore monosulfactam BAL30072 and carbapenems on multidrug-resistant Gram-negative bacilli

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

In vitro activity of BAL30072 against Burkholderia pseudomallei

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

In vitro activity of the siderophore monosulfactam BAL30072 against contemporary Gram-negative pathogens from New York City, including multidrug-resistant isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

In vitro and in vivo activities of LCB01-0371, a new oxazolidinone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Antimicrobial lexitropsins containing amide, amidine, and alkene linking groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Spectrum of activity and mode of action of REP3123, a new antibiotic to treat Clostridium difficile infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

In vitro and in vivo activities of the nitroimidazole TBA-354 against Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Contribution of the nitroimidazoles PA-824 and TBA-354 to the activity of novel regimens in murine models of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Clavulanic acid: a beta-lactamase-inhiting beta-lactam from Streptomyces clavuligerus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

New β-lactam-β-lactamase inhibitor combinations in clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

β-Lactam Antibiotics Renaissance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Activity of biapenem (RPX2003) combined with the boronate β-lactamase inhibitor RPX7009 against carbapenem-resistant Enterobacteriaceae

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Two decades of imipenem therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging gram-negative organisms, including metallo-β-lactamase producers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

OP0595, a new diazabicyclooctane: mode of action as a serine β-lactamase inhibitor, antibiotic and β-lactam 'enhancer'

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

In vivo activities of simulated human doses of cefepime and cefepime-AAI101 against multidrug-resistant Gram-negative Enterobacteriaceae

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

In Vitro Activity of Cefepime/AAI101 and Comparators against Cefepime Non-susceptible Enterobacteriaceae

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Alternatives to antibiotics—a pipeline portfolio review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Antibiotic resistance breakers: can repurposed drugs fill the antibiotic discovery void?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Mining the microbial dark matter

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Mapping gene clusters within arrayed metagenomic libraries to expand the structural diversity of biomedically relevant natural products

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Fraunhofer to mine Sanofi microbial collection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

A community-based approach to new antibiotic discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Helping Chemists Discover New Antibiotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Erratum: A new antibiotic kills pathogens without detectable resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

Fluorocyclines. 2. Optimization of the C-9 side-chain for antibacterial activity and oral efficacy

21 January 2018

1 reference

12 December 2020

BEAM to fight antimicrobial resistance

1 reference

12 December 2020

Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles

1 reference

12 December 2020

1 reference

12 December 2020

Antitubercular activity in vivo of nicotinaldehyde thiosemicarbazone and its isomers

1 reference

12 December 2020

Development of new antibiotics: taking off finally?

1 reference

12 December 2020

Second MRSA antibiotic reaches the market

1 reference

12 December 2020

Antimicrobial activity of the novel pleuromutilin antibiotic BC-3781 against organisms responsible for community-acquired respiratory tract infections (CARTIs)

1 reference

12 December 2020

Zabofloxacin versus moxifloxacin in patients with COPD exacerbation: a multicenter, double-blind, double-dummy, randomized, controlled, Phase III, non-inferiority trial

1 reference

12 December 2020

Editorial overview: Anti-infectives: Current challenges and unmet needs in antimicrobial therapy

1 reference

12 December 2020

SMT19969 for Clostridium difficile infection (CDI): in vivo efficacy compared with fidaxomicin and vancomycin in the hamster model of CDI.

1 reference

12 December 2020

In vitro activity of tedizolid (TR-700) against linezolid-resistant staphylococci

1 reference

12 December 2020

The antibiotic resistance crisis: part 1: causes and threats

1 reference

12 December 2020

Piperacillin-tazobactam: a beta-lactam/beta-lactamase inhibitor combination

1 reference

12 December 2020

Antibiotic 6640, a new Micromonospora-produced aminoglycoside antibiotic

1 reference

12 December 2020

The new tuberculosis drug Perchlozone® shows cross-resistance with thiacetazone

1 reference

12 December 2020

The antibiotic resistance crisis: part 2: management strategies and new agents

1 reference

12 December 2020

The structure of sisomicin, a novel unsaturated aminocyclitol antibiotic from Micromonospora inyoensis

1 reference

12 December 2020

In vitro activity of the siderophore monosulfactam BAL30072 against meropenem-non-susceptible Acinetobacter baumannii

1 reference

12 December 2020

Synthesis and beta-lactamase inhibitory properties of 2 beta-[(1,2,3-triazol-1-yl)methyl]-2 alpha-methylpenam-3 alpha-carboxylic acid 1,1-dioxide and related triazolyl derivatives

1 reference

12 December 2020

Naturally-occurring beta-lactamase inhibitors with antibacterial activity

1 reference

12 December 2020

Selection and characterisation of Staphylococcus aureus mutants with reduced susceptibility to the investigational oxazolidinone MRX-I

1 reference

12 December 2020

A concise synthesis of a β-lactamase inhibitor

1 reference

12 December 2020

Activity of the new quinolones WCK 771, WCK 1152 and WCK 1153 against clinical isolates of Streptococcus pneumoniae and Streptococcus pyogenes

1 reference

12 December 2020

In vitro susceptibilities of clinical isolates of ertapenem-non-susceptible Enterobacteriaceae to nemonoxacin, tigecycline, fosfomycin and other antimicrobial agents

1 reference

12 December 2020

Mechanism of action of oritavancin and related glycopeptide antibiotics

1 reference

12 December 2020

The pleuromutilin antibiotics: a new class for human use.

1 reference

12 December 2020

ANTIBIOTIC 6640, A NEW MICROMONOSPORA-PRODUCBD AMINOGLYCOSIDE ANTIBIOTIC

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

7 January 2021

inferred from DOI database lookup

Clavulanic acid, a novel β-lactam isolated from Streptomyces clavuligerus; X-ray crystal structure analysis

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.72

7 January 2021